SEOUL, South Korea, Nov. 15, 2016 /PRNewswire/ -- Seegene and Institut Català d'Oncologia (ICO), a world-renowned cancer institute in Spain, have entered into collaboration in conducting clinical studies of Seegene's molecular diagnostic products and developing products related to cancer diagnosis. Seegene Inc. (096530.KQ, CEO Jong-Yoon Chun), the world's leading developer of multiplex molecular technologies & assays, today (15 th November, local time), announced the conclusion of an MOU with the ICO for cooperation in clinical research and development of new cancer related products. Dr. Josep Maria Vilà (president of the ICO), Dr. Silvia de Sanjosé (chief of Cancer Epidemiology Research Program, ICO), and Dr. Xavier Bosch (senior consultant of CERP and the ICO & eminent expert in HPV prevention) attended the signing ceremony, drawing nationwide attention in Spain to the MOU between Seegene and the ICO. ICO, one of the most authoritative cancer laboratories in Europe, has built unequaled research and service accomplishments in diagnosis and treatment of various cancers that include cervical cancer, head & neck cancer as well as endometrial cancer. Through mutual cooperation with the ICO, Seegene plans to conduct clinical research with various cancer-related clinical specimens and to develop new cancer screening products. The MOU with the ICO is the first step toward Seegene's 'Project 100: One platform MDx Solution', its new strategy to diversify its product portfolio. Seegene's Project 100, built on its innovative SG Oligo and automated assay development system, aims at developing about 100 new molecular diagnostic products within the next two years by atomizing the whole processes of product development, clinical trial, manufacturing and quality control. All new developed MDx assays can be operated on Seegene's one automation platform. This will present an uncharted direction to the molecular diagnostics industry in which most molecular detection tests covered on one platform, just like other commonly used diagnostics such as immunodiagnostics and biochemical diagnostics.